Plenur

Quick links to important sections

Plenur

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Plenur

Property Description
Active ingredient Lithium carbonate
Form Prolonged-release tablet (oral formulation)
Pharmacological class Mood stabilizer / Antimanic agent
Common use Regulation of affective disorders
Origin Inorganic salt (chemical compound)

What Type of Medication is Plenur? (Identity and Classification)

Plenur is a prescription-only medication classified as a psychotropic agent and formally categorized as an antimanic agent or mood stabilizer. This designation signifies the drug's core function: the long-term regulation of severe, cyclical mood disturbances associated with affective disorders. The active substance, Lithium carbonate, is the standard for this class. This classification means the medication’s primary role is to bring stability to extreme mood fluctuations. Plenur is often associated with the Spanish pharmaceutical manufacturer Faes Farma, and its active substance is listed on the WHO Model List of Essential Medicines for its critical public health value.

Composition and Physical Form of Plenur (Substance and Delivery)

The foundational chemistry of Plenur centers on Lithium carbonate (INN), an inorganic salt element that releases the Lithium ion (Li^+) in the body. The medication is typically administered as an oral formulation, manufactured as a prolonged-release tablet, often marketed as Plenur Retard. The design of this sustained-release tablet is fundamental to the drug’s identity, as it ensures a gradual and consistent absorption of the Lithium carbonate over time, mitigating the risk of rapid concentration spikes. The prolonged-release form is designed to deliver the active substance steadily for continuous regulation.

What is the General Purpose of Plenur's Action? (High-Level Benefit)

The general purpose of Plenur is to provide fundamental, long-term neurochemical regulation that stabilizes the patient's emotional state. The Lithium ion acts as a CNS agent to modulate the activity of brain messengers and stabilize critical internal cell signaling pathways. This action is crucial for stabilizing typical use scenarios, such as preventing the recurrence of manic or depressive episodes. By intervening in these key communication systems, the medication’s action translates into a clinical benefit of reducing the intensity and recurrence of volatile mood episodes, which is essential for ongoing stability.

Regulatory References

  1. WHO Model List of Essential Medicines

What side effects are possible with Plenur?

The safety profile for Plenur (Lithium carbonate) is structured around the potential for effects on the nervous, renal, and endocrine systems, as documented in official regulatory labeling. The most frequently observed adverse reactions, sometimes noted upon the initiation of therapy, include fine hand tremor, polyuria (excessive urination), polydipsia (excessive thirst), and gastrointestinal discomfort like nausea.

Serious and Time-Related Safety Considerations

The primary serious risk is Lithium Toxicity (poisoning), which is closely related to the concentration of Lithium in the blood and requires mandatory serum monitoring. Other serious adverse reactions listed in regulatory documents include the risk of Serotonin Syndrome, Encephalopathic Syndrome, and the unmasking of Brugada Syndrome.

Long-term exposure is specifically associated with the potential for developing Chronic Kidney Disease and Hypothyroidism (underactive thyroid). These effects relate to the drug's influence on kidney function and hormone regulation.

Population-Specific Safety and Restrictions

Specific safety considerations are documented for certain populations. The use of the medication during pregnancy is associated with a risk of fetal cardiac anomalies, such as Ebstein's anomaly. Older adults and individuals with pre-existing renal or cardiovascular disease are at a heightened risk of drug accumulation and toxicity due to compromised elimination. Consequently, the drug is generally restricted for use in cases of severe dehydration or sodium depletion, as these conditions markedly elevate the risk of toxicity.

Overdose and Emergency Response

Overdose and when to seek help

Lithium carbonate (Plenur) is officially documented as having a narrow therapeutic index, meaning the difference between effective and toxic concentrations is small. The appearance of any clinical sign of toxicity requires immediate medical attention and discontinuation of the medication, as mandated by regulatory authorities.

Documented Overdose Manifestations

Initial overdose presentations, as listed in government labeling, include gastrointestinal signs (nausea, vomiting, diarrhea) and mild neurological signs such as coarse tremor, drowsiness, slurred speech, and a lack of coordination (ataxia). These symptoms indicate a potentially dangerous situation.

Required Emergency Actions

The regulatory guidance is strict: The patient must discontinue therapy immediately and contact emergency medical services or a physician. Urgent hospital monitoring is required in all suspected overdose cases. Severe toxicity can rapidly progress to life-threatening outcomes, including seizures, cardiac arrhythmias, and acute renal failure.

Management and Key Regulatory Statements

No specific antidote is known for lithium poisoning. Management relies on symptomatic and supportive treatment, including necessary procedures like frequent serum Lithium concentration determinations and monitoring of cardiac and renal function. Hemodialysis is documented as the essential procedure for drug removal in severe or life-threatening intoxications.

Therapeutic Uses of Plenur

Main Uses and Therapeutic Benefits of Plenur

Plenur is commonly used across conditions characterized by periods of heightened symptoms related to affective instability. This medication is considered relevant in conditions involving episodic or fluctuating manifestations, including bipolar disorder, acute manic episodes, and as augmentation therapy for certain cases of treatment-resistant depression. Its role is in supporting the patient during difficult episodes by helping to address symptom clusters that may become intense or disruptive.

Symptom Management and Stability

The medication is applied in clinical settings that involve acute or unstable symptom patterns, relevant for managing symptoms that interfere with daily comfort. This is used for managing symptom clusters that may become intense or disruptive, such as extreme hyperactivity, agitation, and accelerated thought processes, as well as symptoms related to behavioral dysregulation, like hostility or self-harming actions. It is considered relevant for easing symptoms driven by heightened physiological activity.

“The goal of treatment is to provide support that helps ease the overall symptom burden and contribute to improved comfort during symptomatic periods.”

Quick Fact: Relief for Volatile Mood Extremes

Plenur may assist with managing symptoms that interfere with daily comfort, providing supportive relief when symptoms interfere with routine activities.

Regulatory References

  1. NIH MedlinePlus overview on Lithium

Eligibility and Restrictions for Use

The official regulatory profile for Plenur (Lithium carbonate) establishes strict eligibility criteria based on critical organ function and life stage.

Populations for Whom Use is Contraindicated

Use of this medicine is formally prohibited (contraindicated) for individuals with:

  • Severe Renal Disease (severe kidney impairment).
  • Significant Cardiovascular Disease (especially heart rhythm disorders).
  • Brugada Syndrome (or a family history of the condition).
  • States of Severe Dehydration, Debilitation, or Sodium Depletion, as these conditions significantly increase the risk of severe toxicity.

Age and Life Stage Eligibility

Population Group Regulatory Eligibility Status
Adults Eligible for approved uses.
Children under 12 Not recommended for extended-release formulation; safety and effectiveness not established.
Older Adults Requires caution due to increased susceptibility to toxicity.
Pregnancy Generally not recommended in the first trimester due to potential fetal harm.
Lactation Contraindicated or strongly advised against, as the substance is excreted in human milk.

Condition-Specific Limitations

Patients with mild to moderate kidney impairment require close medical supervision. Use alongside other medications that affect kidney function, such as diuretics or ACE inhibitors, is restricted and requires careful monitoring to prevent lithium accumulation.

What should I know about interactions with other medicines?

Interactions Modifying Exposure (Pharmacokinetic Risk)

Official regulatory information indicates that Plenur's most significant interactions involve the renal clearance of the lithium ion. Medications that reduce the kidney's ability to excrete lithium can lead to increased serum lithium concentrations and a high risk of toxicity. These agents include Diuretics (especially thiazides), Angiotensin-Converting Enzyme (ACE) Inhibitors, and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) such as Indomethacin or Piroxicam. Co-administration with these categories is often classified as contraindicated or requiring extreme caution. Conversely, some substances, like Acetazolamide, are documented to increase urinary lithium excretion, potentially reducing exposure. The maintenance of a normal and consistent dietary sodium and fluid intake is officially required, as sodium loss is documented to reduce lithium clearance.

Pharmacodynamic and Procedural Constraints

Additional interactions are categorized as pharmacodynamic (PD), involving additive effects on the central nervous system (CNS). Concurrent use with Serotonergic Drugs (e.g., SSRIs, Triptans, and the herbal product St. John's Wort) increases the documented risk of Serotonin Syndrome. Combining Plenur with certain Neuroleptics, particularly Haloperidol, is associated with a reported risk of Encephalopathic Syndrome. Furthermore, the official prescribing information includes a procedural restriction: the medication is required to be stopped 24 hours prior to major surgery. Caution is also formally noted for Elderly Patients and those with Brugada Syndrome, as these populations may be at heightened risk for interaction severity.

Mechanism of Action

Plenur, featuring the Lithium ion ( Li^+) as its active species, exerts a complex, pleiotropic mechanism of action primarily within the central nervous system (CNS). The core action involves the simultaneous modulation of several critical intracellular signaling pathways, influencing the overall balance of neuronal activity.


Intracellular Signal Damping and Enzyme Inhibition

The Li^+ ion acts as an inhibitor of central enzymes, notably Glycogen Synthase Kinase-3 (GSK-3) and Inositol Monophosphatase (IMPase). This action disrupts the turnover of the Phosphatidylinositol (PI) cycle and other messenger systems, modulating intracellular signaling cascades associated with heightened neuronal activity at the cellular level.


Neurotransmitter and Pathway Rebalancing

The mechanism extends to chemical communication by promoting the function of inhibitory neurotransmitters (like GABA) while simultaneously attenuating or reducing the impact of highly excitatory neurotransmitter systems (such as glutamate). This targeted modulation of neural pathways influences the overall chemical tone of neural circuits.


Neuroplasticity and Cellular Resilience

Chronic action of Li^+ enhances the expression of neurotrophic factors, including Brain-Derived Neurotrophic Factor (BDNF). This promotes neuronal survival and plasticity, and influences the persistence of neuronal function, which is critical for long-term physiological regulation.

Dosage and Administration Information

Plenur is an oral formulation administered as a prolonged-release tablet. The official usage protocol requires that the tablet must be swallowed whole and never chewed or crushed to preserve the controlled-release kinetics essential for maintaining stable plasma concentrations. The medication is typically administered twice daily (b.i.d.), with doses spaced at approximately 12-hour intervals, and is preferably taken with food to enhance gastrointestinal tolerance.

The dosage regimen is highly individualized and determined by Therapeutic Drug Monitoring (TDM). For acute management, total daily doses (TDD) may reach 1800 mg, aiming for a serum lithium concentration between 1.0 and 1.5 mEq/L. For long-term maintenance to prevent recurrence, the TDD is generally 900 mg to 1200 mg, targeting a lower serum level between 0.6 and 1.2 mEq/L.

This TDM requirement is fundamental: dosages are adjusted based on blood samples for lithium determination, which must be accurately drawn 8 to 12 hours after the previous dose to measure the trough level. Monitoring is frequent during initial stabilization and continues at least every two months during maintenance. Furthermore, proper use requires the patient to maintain a normal salt diet and adequate fluid intake (2500 –3000 mL daily) throughout the duration of treatment, as these factors critically influence drug concentration. Specific usage rules apply to certain populations: older adults often require a reduced dosage, and the extended-release form is not generally recommended for children under 12 years of age.

Recent Clinical Evidence

Evidence for Monotherapy Use

Research has explored the relationship between this drug (Lithium Carbonate) and measures of the quality of life, and evaluated the impact on disease activity markers for participants with mood disorders. Studies examined the drug’s relationship to changes in inflammation markers, and adverse events were documented in people with moderate symptoms. Controlled trials have indicated that the use of this drug is associated with a lower rate of suicide and deliberate self-harm in patients with recurrent mood disorders compared to other compounds or placebo.

  • Key Findings: Research reported findings on various patient outcomes, including changes in fatigue and pain scores, and overall illness severity. The most consistent findings relate to its long-term use in reducing the risk of suicide in both unipolar and bipolar depression.
  • Safety Profile: Adverse events, including gastrointestinal issues and skin reactions, were documented in the research.

Research on Dosing and Administration

Research studied a dosing schedule that often involved starting with a low dose to assess the impact on side effects. Low-dose lithium has been studied as an adjunct therapy in unipolar depression and for potential neuroprotective effects.

Dosing Feature Research Focus
Dose Escalation Studies reviewed the findings related to increasing the dose gradually.
Maintenance Dose Trials examined specific daily amounts required to maintain therapeutic blood levels.

Combination Therapy Studies

A study of combination therapy investigated whether combining this drug with other mood stabilizers was associated with specific response rates. Researchers analyzed the findings for this combination and monotherapy, with some trials suggesting that combining it with optimized treatment may offer benefits without compromising tolerability. Studies also explored the association with long-term complications, such as kidney impairment, often linked to maintaining higher therapeutic levels.

Key Studies & References NICE Guideline: Bipolar disorder: assessment and management (Focus on monitoring requirements and dosing)

Frequently Asked Questions (FAQ)

Common questions about Plenur (FAQ)


Q: How quickly does Plenur typically start working after I begin taking it?

Official information indicates that the stabilization of severe mood symptoms often begins to appear within one to three weeks after a person starts taking Plenur. Because the medication requires careful and gradual adjustment to find the right therapeutic level, it may take some time for the optimal therapeutic level to be reached.


Q: Does Plenur cause weight gain or weight loss in most users?

Regulatory safety documents for the active ingredient in Plenur list excessive weight gain as a potential common adverse reaction. Unexpected changes in weight are typically reviewed by a healthcare provider.


Q: Is it normal to feel a bit tired or dizzy when first starting Plenur?

Official safety documents include dizziness, drowsiness, and unusual tiredness as possible side effects. These nervous system effects may be more noticeable when first beginning the medication or following a change in regimen.


Q: Can Plenur affect my sleep patterns?

The active ingredient in Plenur can cause side effects like drowsiness and other central nervous system effects that may impact wakefulness. Additionally, a common side effect is polyuria (increased urination), and this side effect may be associated with disruptions to sleep patterns.


Q: Does Plenur interact with birth control pills?

No specific interaction that affects the effectiveness of common oral contraceptives is generally reported in the professional prescribing information. The professional prescribing information advises that a healthcare professional review all concurrent medications before starting or stopping treatment.


Q: How does Plenur affect a person's ability to drive or operate machinery?

Official patient information advises that Plenur can cause side effects like dizziness, drowsiness, and difficulty concentrating. Patients who experience these effects are typically advised to use caution when driving or operating hazardous machinery.


Q: Is there a generic version of Plenur available?

The active ingredient in Plenur is Lithium Carbonate. Generic versions of Lithium Carbonate extended-release tablets, as well as other formulations of the substance, are commonly available. These medications contain the same active chemical compound.


Q: What happens if I accidentally take two doses of Plenur close together?

Signs of Lithium Toxicity (poisoning) can occur, which are serious and require immediate attention. Official warnings state that if signs (such as severe vomiting, diarrhea, noticeable tremor, or unusual drowsiness) appear, the medication should be discontinued and emergency medical attention should be sought.


Q: Is Plenur considered a controlled substance?

No, Plenur is a prescription-only drug and is classified as a psychotropic agent, but its active ingredient is not currently listed as a controlled substance under U.S. regulatory acts.


Q: How long does Plenur stay in your system after you stop taking it?

Regulatory pharmacokinetic data suggests the half-life of elimination for the active ion is approximately 24 hours. This reflects the time it takes for half of the drug to be cleared from the body. The exact rate of clearance can vary significantly based on an individual's kidney function.


Q: Does Plenur interact with alcohol?

Yes, official patient information advises that alcohol can increase nervous system side effects of the medication, such as dizziness and drowsiness. This combination may potentially impair thinking and judgment.


Q: What should I do if the side effects of Plenur feel severe?

The official label explicitly warns that if signs of Lithium Toxicity occur—such as severe vomiting, confusion, severe drowsiness, or muscle weakness—the medication should be discontinued. The patient must seek emergency medical attention in these cases.


Q: Can Plenur affect the results of common blood tests?

Official documents note that the drug can affect the levels of certain hormones (like thyroid hormones) and elements (like calcium). These parameters often require regular monitoring via blood tests while taking the medication.


Q: What are the signs of a possible allergic reaction to Plenur?

Common adverse reactions listed in the regulatory documents include a rash and an acne-like rash. If symptoms include swelling of the face, tongue, or throat, or severe difficulty breathing, these are documented as potential signs of a serious systemic reaction that warrants immediate medical review.


Q: Does Plenur carry a Boxed Warning in the official prescribing information?

Yes, Plenur carries a Boxed Warning in the official prescribing information. This is the strongest warning required by the FDA and highlights the serious risk of Lithium Toxicity, which is directly tied to the concentration of the drug in the blood.


Q: If I am taking multiple medications, what is the best way to check for Plenur interactions?

Official patient information states that you should inform your doctor or pharmacist about all other medications, vitamins, and herbal products you are using. Official information indicates that this comprehensive discussion is essential for checking for potential interactions.


Q: Are there any major food groups or drinks to be cautious about while using Plenur?

Regulatory documents state that patients are required to maintain a normal salt diet and adequate fluid intake throughout treatment. Large, sudden changes in either sodium or fluid intake can cause the medication's level in the blood to change, which can be dangerous.


Q: Is Plenur safe to take if I also take over-the-counter pain relievers?

Official information specifically warns against taking Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as Ibuprofen, as they can raise the concentration of Plenur in the blood. This increase can significantly raise the risk of toxicity.


Q: Are there any known interactions between Plenur and herbal supplements?

Official guidelines recommend caution or avoidance when combining the drug with herbal products, such as St. John's Wort, that are known to affect serotonin levels. This is due to a documented risk of Serotonin Syndrome.


Q: Do children or teenagers ever use Plenur?

The prolonged-release form of Plenur is not generally recommended for children under 12 years of age. Official regulatory bodies indicate that the safety and effectiveness of this specific formulation have not been established for this age group.


Q: Are there any lifestyle changes that can help Plenur work better?

The proper functioning of Plenur requires patients to maintain a normal salt diet and adequate fluid intake (e.g., 2500 –3000 mL daily). Conditions that lead to fluid or salt loss, such as excessive sweating or diarrhea, may necessitate compensating with supplemental fluid and salt.


Q: Can women who are planning to become pregnant use Plenur?

The official label notes that the drug may cause fetal harm and is generally not recommended during pregnancy, particularly in the first trimester. The need for contraception and discussion of treatment alternatives is typically addressed with a healthcare provider.


Q: How does the effectiveness of Plenur compare between different age groups?

The dose is often reduced for older adults due to their increased susceptibility to toxicity. For children under 12 years of age, official documents indicate that safety and effectiveness are not established for this formulation.


Q: Are there any special considerations for people with kidney or liver issues using Plenur?

Use is strictly prohibited (contraindicated) for individuals with severe renal (kidney) disease because the drug is primarily eliminated by the kidneys. There is no specific contraindication noted solely for liver issues in the regulatory documents.


Q: Are there different forms of Plenur (tablet, liquid, extended-release)?

The Plenur brand is manufactured specifically as a prolonged-release tablet. However, the active chemical ingredient, Lithium Carbonate, is widely available from other manufacturers in various formulations, including standard immediate-release tablets or capsules and a liquid oral solution.

How should Plenur be stored and disposed of?

How to Store and Dispose of Plenur

Storage of Plenur (Lithium carbonate prolonged-release tablets) must strictly follow official regulatory requirements to maintain product integrity.


Official Storage Conditions

The medication should be stored at Controlled Room Temperature, which is between 20 C to 25 C (68 F to 77 F), with permitted short-term temperature excursions up to 30 C. The product must be stored below 25 C.

Condition Requirement
Temperature Store below 25 C / Controlled Room Temperature
Protection Keep in the original package to protect from moisture and keep tightly closed
Child Safety Store out of the sight and reach of children

Disposal Instructions

Unused or expired Plenur should be safely disposed of through an authorized drug take-back program. If a take-back program is unavailable, it should be mixed with an undesirable substance (e.g., coffee grounds), sealed in a container, and discarded in the household trash. The medication is not recommended for flushing down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Plenur found in:

A-Z Index: